Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9333MR)

This product GTTS-WQ9333MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF18 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_004195.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8784
UniProt ID Q9Y5U5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9333MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10235MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ8464MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ12598MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ1451MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ4885MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ10733MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ7363MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ11423MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-8897
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW